Background
Carotid body tumors (CBTs) are rare neoplasms, although they represent about 65% of head and neck paragangliomas.[1] These tumors develop within the adventitia of the medial aspect of the carotid bifurcation.
The carotid body, which originates in the neural crest, is important in the body's acute adaptation to fluctuating concentrations of oxygen, carbon dioxide, and pH. The carotid body protects the organs from hypoxic damage by releasing neurotransmitters that increase the ventilatory rate when stimulated.
See the image below.
Proximal and distal control of the carotids with vessel loops. The following 3 different types of carotid body tumors (CBTs) have been described in the literature:
- Familial
- Sporadic
- Hyperplastic
The sporadic form is the most common type, representing approximately 85% of carotid body tumors (CBTs). The familial type (10-50%) is more common in younger patients. The hyperplastic form is very common in patients with chronic hypoxia, which includes those patients living at a high altitude (> 5000 feet above sea level), like those patients living in New Mexico, Peru, and Colorado.[2] The hyperplastic form is also seen in patients who have chronic obstructive pulmonary disease (COPD) or cyanotic heart disease.
History of the Procedure
Descriptions of surgery for carotid body tumors have existed for over 100 years. The early reports described significant complications, particularly mortalities secondary to intraoperative bleeding.[3, 4, 5]
In the United States, the earliest successful carotid body tumor resection was performed by Scudder in 1903.[3]
Even into the middle of the 20th century, resecting these tumors remained a problem because of the complications; Hayes Martin, in his textbook of head and neck tumors, recommended against resection of any tumor that is now considered a Shamblin type III (see Staging).[6]
Modern imaging and current surgical and vascular techniques have significantly improved the safety and success of this operation.
Epidemiology
Frequency
Parasympathetic paragangliomas are rare, with a prevalence of 1-2 per 100,000 population.[7] Carotid body tumors (CBTs) constitute about 65% of head and neck paragangliomas.
Carotid body tumors (CBTs) can occur in children; however, carotid body tumors (CBTs) are considered to be a disease of middle age. The mean age of onset is reported to be 45 years.[8] Paragangliomas are inherited in 10-50% of cases. Age of onset in the hereditary group is typically younger, in the second to fourth decade.[9]
About 5% of carotid body tumors (CBTs) are bilateral and 5-10% are malignant, but these rates are much higher in patients with inherited disease.[10, 11, 12] Familial tumors are found to be 5.8 times more common among patients who have carotid body tumors as compared with patients who have paragangliomas at other sites.
Interestingly, the male-to-female ratio differs in patients dwelling at high altitudes above 2,000 meters (1:8.3) than those patients dwelling at sea level (1:1.0-1.4).[13]
Etiology
The only known risk factors are the presence of chronic hypoxic stimulation and the genetic predisposition.
Pathophysiology
Carotid body tumors (CBTs) are classified into sporadic, familial, and hyperplastic forms. The familial paraganglioma form is a genetically heterogenous entity; currently, 4 genes are identified. The first 3 genes encode the subunits of the enzyme succinate dehydrogenase complex, which is part of the Kreb's cycle. Paraganglioma (PG) syndrome 1, 3, and 4 occur because of mutations of the corresponding genes of the subunits D, C, and B.[14] PG syndrome 2 gene mutations are yet to be identified.
Defective succinate dehydrogenase has been postulated to cause an increase in the intracellular concentration of molecular hypoxia mediators and the vascular endothelial growth factor (VEGF) thus resulting in hyperplasia, angiogenesis, and neoplasia.[7]
In patients who lack a positive family history, germline mutations in the PGL susceptibility genes are still possible via multiple causes, including genomic imprinting, reduced penetrance, or de novo mutations in the genes of the parental gametes.[14]
Chronic hypoxic conditions, such as patients living at high altitudes or those who have chronic obstructive pulmonary disease (COPD) or cyanotic heart problems, can overburden the carotid bodies and subsequently lead to hypertrophy, hyperplasia, and neoplasia of the chief cells.[14] This condition is seen in the hyperplastic type of carotid body tumors (CBTs). However, the mechanism by which reduced oxygen concentrations can lead to CB hyperplasia is unclear.
Finally, carotid body tumors (CBTs) can be occasionally coupled with nonparaganglonic tumors in syndromes including MEN type II, von Hippel-Lindau syndrome, and neurofibromatosis type 1.
Presentation
Carotid body tumors (CBTs) present most commonly as an asymptomatic palpable neck mass in the anterior triangle of the neck. They are slow-growing tumors that can remain asymptomatic for many years. The doubling time (TD) of carotid body tumors (CBTs), as estimated by Jansen et al using sequential imaging, was 7.13 years with a median growth rate of 0.83 mm/year.[15]
On examination, the mass is typically vertically fixed because of its attachment to the bifurcation of the common carotid (Fontaine sign). A bruit can be felt; however, the absence of a bruit does not rule out a carotid body tumor (CBT). Vagal body tumors are more cranially located and sometimes project into the lateral pharynx as a pulsatile mass.
Approximately 10% of the cases present with cranial nerve palsy with paralysis of the hypoglossal, glossopharyngeal, recurrent laryngeal, or spinal accessory nerve, or involvement of the sympathetic chain.[16] Carotid body tumors (CBTs) may, therefore, be associated with pain, hoarseness, dysphagia, Horner syndrome, or shoulder drop.
As the tumor enlarges and compresses the carotid artery and the surrounding nerves, other symptoms may also be present, such as pain, tongue paresis, hoarseness, Horner syndrome, and dysphagia.
Fever is an uncommon sign of carotid body tumor (CBT), although the literature has reported it as one of the causes of fever of unknown origin.[17] In cases of functional carotid body tumors (CBTs), symptoms similar to those of pheochromocytoma, such as paroxysmal hypertension, palpitations, and diaphoresis, are seen.
Relevant Anatomy
The carotid body is a small, reddish-brown, oval structure, located in the posteromedial aspect of the carotid artery bifurcation. The healthy gland measures 3-5 mm in diameter and weighs less than 15 mg on average.[18] The vast majority of the literature states that the gland is located in the adventitia near the carotid artery bifurcation. However, according to Maxwell et al, most surgeons experienced with carotid body dissection maintain that it is more peripherally located, within periadventitial tissue. This distinction is critical, as dissections in the deeper planes of the carotid artery are associated with higher risk for complications from vessel injury.[19]
The gland is highly vascular and receives its blood supply from feeder vessels running through the Mayer ligaments, primarily from the external carotid artery, typically the ascending pharyngeal artery. It is innervated by the Hering nerve, originating from the glossopharyngeal nerve about 1.5 cm distal to the jugular foramen.[20]
Georgiadis GS, Lazarides MK, Tsalkidis A, Argyropoulou P, Giatromanolaki A. Carotid body tumor in a 13-year-old child: Case report and review of the literature. J Vasc Surg. Apr 2008;47(4):874-880. [Medline].
Sajid MS, Hamilton G, Baker DM;. A multicenter review of carotid body tumour management. Eur J Vasc Endovasc Surg. Aug/2007;34:127-30. [Medline]. [Full Text].
Shamblin WR, ReMine WH, Sheps SG, Harrison EG Jr. Carotid body tumor (chemodectoma). Clinicopathologic analysis of ninety cases. Am J Surg. Dec 1971;122(6):732-9. [Medline].
Mitchell RO, Richardson JD, Lambert GE. Characteristics, surgical management, and outcome in 17 carotid body tumors. Am Surg. Dec 1996;62(12):1034-7. [Medline].
Naughton J, Morley E, Chan D, Fong Y, Bosanquet D, Lewis M. Carotid body tumours. Br J Hosp Med (Lond). Oct 2011;72(10):559-64. [Medline].
H Martin. Surgery of Head and Neck Tumors. In: Surgery of Head and Neck Tumors. New York: Hoeber-Harper Books; 1957.
Sevilla Garcia MA, Llorente Pendas JL, Rodrigo Tapia JP, Garcia Rostan G, Suarez Fente V, Coca Pelaz A. [Head and neck paragangliomas: revision of 89 cases in 73 patients]. Acta Otorrinolaringol Esp. Mar 2007;58(3):94-100. [Medline].
Kotelis D, Rizos T, Geisbusch P, Attigah N, Ringleb P, Hacke W, et al. Late outcome after surgical management of carotid body tumors from a 20-year single-center experience. Langenbecks Arch Surg. Mar 2009;394(2):339-44. [Medline].
Jani P, Qureshi AA, Verma S, Walker L. Familial carotid body tumours: is there a role for genetic screening?. J Laryngol Otol. Sep 2008;122(9):978-82. [Medline].
JL Netterville, KM Reilly D, Robertson, ME Reiber, WB Armstrong and P. Childs. Carotid body tumors: a review of 30 patients with 46 tumors. Laryngoscope. 1995;105:114-126.
Karatas E, Sirikci A, Baglam T, Mumbuc S, Durucu C, Tutar E. Synchronous bilateral carotid body tumor and vagal paraganglioma: a case report and review of literature. Auris Nasus Larynx. Mar 2008;35(1):171-5. [Medline].
Gardner P, Dalsing M, Weisberger E, Sawchuk A, Miyamoto R. Carotid body tumors, inheritance, and a high incidence of associated cervical paragangliomas. Am J Surg. Aug 1996;172(2):196-9. [Medline].
Barnes L, Tse LLY, Hunt JL. Carotid Body Paragangliomas. In: Pathology and Genetics of Head and Neck Tumors. IARC. 2005:364-365.
Baysal BE, Myers EN. Etiopathogenesis and clinical presentation of carotid body tumors. Microsc Res Tech. Nov 1 2002;59(3):256-61. [Medline].
Jansen JC, van den Berg R, Kuiper A, van der Mey AG, Zwinderman AH, Cornelisse CJ. Estimation of growth rate in patients with head and neck paragangliomas influences the treatment proposal. Cancer. Jun 15 2000;88(12):2811-6. [Medline].
Isik AC, Imamoglu M, Erem C, Sari A. Paragangliomas of the head and neck. Med Princ Pract. 2007;16(3):209-14. [Medline].
Ghoreishi M, Akbar-Beigi A, Tahery D, Sehhat S. Fever as the main presenting symptom of a carotid body tumor. Arch Iran Med. Mar 2008;11(2):214-7. [Medline].
Lack EE. Anatomy and physiology of peripheral arterial chemoreceptors. In: Pathology of adrenal and extra-adrenal paraganglia. Philadelphia: W.B Saunders; 1-14.
Maxwell JG, Jones SW, Wilson E, Kotwall CA, Hall T, Hamann S. Carotid body tumor excisions: adverse outcomes of adding carotid endarterectomy. J Am Coll Surg. Jan 2004;198(1):36-41. [Medline].
Terry A. Day John K. Joe. Primary Neoplasms of the neck. In: Cummings: Otolaryngology: Head & Neck Surgery. 4th. St Louis: Elsevier-Mosby; 2005:113.
Knight TT Jr, Gonzalez JA, Rary JM, Rush DS. Current concepts for the surgical management of carotid body tumor. Am J Surg. Jan 2006;191(1):104-10. [Medline].
Rosa M, Sahoo S. Bilateral carotid body tumor: the role of fine-needle aspiration biopsy in the preoperative diagnosis. Diagn Cytopathol. Mar 2008;36(3):178-80. [Medline].
Arya S, Rao V, Juvekar S, Dcruz AK. Carotid body tumors: objective criteria to predict the Shamblin group on MR imaging. AJNR Am J Neuroradiol. Aug 2008;29(7):1349-54. [Medline].
Li-Shan L, Chang-Wei L, Heng G, Yue-Hong Z, Xing-Ming C, Yong-Jun L. Efficacy of surgical therapy for carotid body tumors. Chin Med Sci J. Dec 2011;26(4):241-5. [Medline].
Makeieff M, Raingeard I, Alric P, Bonafe A, Guerrier B, Marty-Ane Ch. Surgical management of carotid body tumors. Ann Surg Oncol. Aug 2008;15(8):2180-6. [Medline].
Sahin MA, Jahollari A, Guler A, Doganci S, Bingol H, Karaman B, et al. Results of combined preoperative direct percutaneous embolization and surgical excision in treatment of carotid body tumors. Vasa. Nov 2011;40(6):461-6. [Medline].
Kim H, Cho YP, Moon KM, Kwon TW. Embolic stroke after carotid artery ligation during carotid body tumor resection. Vascular. Nov 18 2011;[Medline].
van der Mey AG, Jansen JC, van Baalen JM. Management of carotid body tumors. Otolaryngol Clin North Am. Oct 2001;34(5):907-24, vi. [Medline].
Antonello M, Piazza M, Menegolo M, Opocher G, Deriu GP, Grego F. Role of the genetic study in the management of carotid body tumor in paraganglioma syndrome. Eur J Vasc Endovasc Surg. Nov 2008;36(5):517-9. [Medline].
Drocos Kotelis, Timolaos Rizos, Philipp Geisbus, et al. Late Outcome after Surgical management of carotid body tumors from a 20-year single-center experience. Langenbecks Arch Surg. 2008.
Gardner P, Dalsing M, Weisberger E, Sawchuk A, Miyamoto R. Carotid body tumors, inheritance, and a high incidence of associated cervical paragangliomas. Am J Surg. Aug 1996;172(2):196-9. [Medline].
Hinerman RW, Amdur RJ, Morris CG, Kirwan J, Mendenhall WM. Definitive radiotherapy in the management of paragangliomas arising in the head and neck: a 35-year experience. Head Neck. Nov 2008;30(11):1431-8. [Medline].
Janda PH, Veerappan V, McKenzie ME, Dhudshia NV. Carotid body tumor as a reversible cause of syncope. J Am Osteopath Assoc. Nov 2011;111(11):638-44. [Medline].
Karatas E, Sirikci A, Baglam T, Mumbuc S, Durucu C, Tutar E. Synchronous bilateral carotid body tumor and vagal paraganglioma: a case report and review of literature. Auris Nasus Larynx. Mar 2008;35(1):171-5. [Medline].
Pellitteri PK, Rinaldo A, Myssiorek D, Gary Jackson C, Bradley PJ, Devaney KO. Paragangliomas of the head and neck. Oral Oncol. Jul 2004;40(6):563-75. [Medline].
Scanlon JM, Lustgarten JJ, Karr SB, Cahan JI. Successful devascularization of carotid body tumors by covered stent placement in the external carotid artery. J Vasc Surg. Nov 2008;48(5):1322-4. [Medline].
van der Bogt KE, Vrancken Peeters MP, van Baalen JM, Hamming JF. Resection of carotid body tumors: results of an evolving surgical technique. Ann Surg. May 2008;247(5):877-84. [Medline].

